AI주식인사이트AI Stock Insight
C

아이엠비디엑스

461030KOSDAQ자연과학 및 공학 연구개발업

52.0 / 100

Reference Date: 2026-06-10

Financial Score26.5 / 40
News Sentiment12.5 / 25
Momentum3.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 36.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

IMBIX is a global healthcare company leading the way in precision cancer diagnosis and early detection using liquid biopsy and next-generation sequencing (NGS) technologies. Its core business areas include precision diagnosis of advanced cancers, early detection of post-surgical recurrence, and early cancer screening, supported by products like AlphaLiquide®100 and HRR.

Number of Employees

65people

Average Salary

58.1M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 62.704.0Point
PBR
2.42Industry Average 3.245.5Point

Lower than industry avg (good)

ROE
-27.54Industry Average -32.093.5Point

Below industry avg

Debt Ratio
1.67Industry Average 7.318.0Point

Half of industry avg (excellent)

Trend 2024~20255.5 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲56.4% (1-year basis)

Operating Profit Growth Rate
2.5 / 3

Avg ▲18.4% (1-year basis)

ROE Trend
0.0 / 4

Avg ROE -37.3% (improving, 2yr)

Detailed News Sentiment

1 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 4,245Won52-week high 12,08052-week low 4,245
1-month return0.0Point

1m -36.92% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral분기보고서 (2026.03)2026-05-15